Business Context and Reporting Period
Company: Caribou Biosciences, Inc. (CRBU)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Caribou is a clinical-stage biopharmaceutical company developing allogeneic (off-the-shelf) CAR-T cell therapies using its proprietary CRISPR chRDNA genome-editing platform. The company focuses on two primary product candidates: vispa-cel (anti-CD19 for B-cell non-Hodgkin lymphoma) and CB-011 (anti-BCMA for multiple myeloma). In April 2025, the company executed a strategic pipeline prioritization, discontinuing preclinical research and two clinical programs (GALLOP and AMpLify) to focus resources on its lead candidates.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Licensing & Collaboration Revenue | $11.2 | $10.0 |
| Net Loss | $(148.1) | $(149.1) |
| Research & Development Expenses | $109.4 | $130.2 |
| General & Administrative Expenses | $37.9 | $46.5 |
| Impairment Charges | $12.2 | $0.0 |
| Cash, Cash Equivalents, & Marketable Securities | $142.8 | $249.4 |
| Accumulated Deficit | $(596.5) | $(448.4) |
Liquidity: As of December 31, 2025, the company held $142.8 million in cash and marketable securities. Management expects these resources to fund operations for at least the next 12 months from the filing date. The company has no debt but relies on equity offerings and licensing revenue.
Material Changes vs. Prior Period
- Expense Reductions: Total operating expenses decreased by $17.1 million to $159.5 million, driven by a $20.7 million reduction in R&D and an $8.5 million reduction in G&A. These decreases were primarily due to workforce reductions (32% reduction in April 2025) and the discontinuation of non-core clinical programs.
- Impairment Charges: The company recorded $12.2 million in impairment charges in 2025 related to leasehold improvements, right-of-use assets, and lab equipment following the strategic pivot. No such charges were recorded in 2024.
- Equity Investment Impairment: A $9.2 million impairment was recorded on an equity investment in Edge Animal Health, reducing the investment balance to zero.
- Revenue Growth: Licensing revenue increased by $1.2 million, primarily due to higher revenue from "other licensees," partially offset by the cessation of revenue from Edge Animal Health.
Guidance, Outlook, and Risks
Clinical Outlook:
- Vispa-cel: The company is planning a pivotal Phase 3 trial in approximately 250 patients with relapsed/refractory large B-cell lymphoma (2L LBCL). Recent Phase 1 data showed an 82% overall response rate in a confirmatory cohort.
- CB-011: Dose expansion for relapsed/refractory multiple myeloma was initiated in late 2025. The Recommended Dose for Expansion (RDE) was identified as 450x10^6 viable CAR-T cells.
Capital Requirements: The company explicitly states it does not have sufficient funds to conduct the planned pivotal trial for vispa-cel and will need to raise additional capital. Failure to secure financing could result in the inability to complete development.
Key Risks:
- Regulatory Uncertainty: Ongoing engagement with the FDA regarding the design of the pivotal trial; no assurance that the proposed design will meet requirements.
- Intellectual Property: Significant ongoing patent interferences regarding foundational CRISPR-Cas9 IP (CVC IP) involving the Broad Institute, ToolGen, and others, which could impact licensing revenue and freedom to operate.
- Manufacturing: Reliance on third-party Contract Manufacturing Organizations (CMOs) for all clinical supplies, including a non-U.S. vendor for viral vectors.
- Stock Listing: The company previously faced Nasdaq delisting risks due to low stock price but regained compliance in June 2025. A reverse stock split is authorized but not yet implemented.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $142.8 million cash balance against the projected costs of the planned pivotal Phase 3 trial for vispa-cel.
- Capital Raise Plans: Monitor for announcements regarding new equity offerings, debt financing, or strategic partnerships required to fund the pivotal trial.
- IP Litigation Status: Track the status of the CRISPR-Cas9 patent interferences (specifically the '115 interference remand) and their potential impact on licensing revenue and product commercialization.
- Regulatory Milestones: Confirm the final agreement with the FDA on the Phase 3 trial design and the timeline for patient enrollment.
- Manufacturing Supply Chain: Assess the stability of relationships with CMOs, particularly the non-U.S. viral vector supplier, and any potential impact from trade regulations (e.g., BIOSECURE Act).